Dual Force Immunotherapies
Double the Power, Double the Hope
Unleashing the Potential Against Cancer and Infectious Diseases
ViferaXS is a pioneering biotech company specializing in cancer immunotherapies based on peptide-based T cell activators that combine tumor-specific antigens with potent immune stimulation.
Our Proprietary Platform for Dual Force Immunotherapy:
Immunopeptidome-based antigen discovery platform enables the fast track design of off-the-shelf immunotherapy solutions
- Naturally presented mutated and non-mutated tumor antigens directly identified on the patient’s tumor cell
- Proprietary tumor antigen warehouse for multiple tumor entities for a fast-track off-the-shelf immunotherapy composition
- Next generation naturally presented neoepitopes
Superior adjuvant formulation that enables the induction of potent and long-lasting T cell responses enhancing the effectiveness of off-the-shelf immunotherapy
Technology
Off-the-shelf therapeutic vaccinations for cancer patients
Our cutting-edge approach utilizes patient-specific tumor-associated antigens to develop off-the-shelf immunotherapy solutions.
Proprietary Platform
Our proprietary platform allows us to rapidly analyze the immunopeptidome, identifying tumor-specific peptides in just a few days.
Adjuvant
XS15 is designed to induce potent and long-lasting tumor-directed T cell responses, enhancing the effectiveness of our off-the-shelf immunotherapy.
Partnering Opportunities
Immunopeptidome Analysis
At ViferaXS, we are advancing a versatile T cell activator platform with strong clinical validation and broad applicability across hematologic and solid tumors. Our approach enables both off-the-shelf, offering opportunities for collaboration from early development to late-stage clinical programs.
Why Partner with ViferaXS?
- Phase II-ready program in Chronic Lymphocytic Leukemia (CLL)
- Clinically validated technology with broad translational potential
- Solid tumor pipeline targeting high unmet needs
Let’s Translate Science into Patient Impact
We welcome discussions with biopharma partners interested in:
- Co-developing programs in specific tumor indications
- Enhancing their immuno-oncology pipeline
- Expanding into peptide-based T cell–based activators
Work with us
Do you want to shape the future with us?
Meet the team
Founders
Prof. Hans-Georg Rammensee
Renowned as a leading immunologist and cancer immunotherapy researcher at the University of Tübingen, Prof. Hans-Georg Rammensee is a key contributor to the project. His groundbreaking work revolves around the biology of MHC molecules and the peptides they present to T cells, the identification of tumor-specific peptides and the developing personalized cancer vaccines based on these peptides. He has authored over 400 scientific papers and received numerous awards and honors.
Prof. Dr. Juliane Walz
Prof. Juliane Walz is a physician trained in hematology and oncology and Head Peptide-based Immunotherapy and Medical Director of the Clinical
Cooperation Unit for Translational Immunology at the University Hospital Tübingen. She brings long-standing expertise in the clinical translation of novel immunotherapeutic strategies, with currently four ongoing clinical trials evaluating in-house developed peptide-based T cell activators.
Sezai Taskin
Sezai Taskin leverages over 20 years of experience in launching and commercializing leading franchises across multiple therapeutic areas. He has held leadership roles in hematology and oncology at AstraZeneca, AbbVie, and Roche.
Throughout his career, Sezai has built and led successful multi-functional, multinational teams, driving business performance and fostering strategic relationships.
Scientific Advisors
Prof. Dr. Karl-Heinz Wiesmüller
Dr. Karl-Heinz Wiesmüller brings more than 25 years of experience in peptide and lipopeptide synthesis, synthetic vaccine development, and immunochemistry. Dr. Wiesmüller has published over 180 scientific papers and held significant leadership positions at EVOTEC BioSystems GmbH and the Natural & Medical Science Institute in Reutlingen. In his last position he was CEO of EMC microcollections GmbH.
News